The ArteraAI team is excited to be at #AUA24 !

Don't miss Todd Morgan MD (Todd 〽️ Morgan, MD)'s presentation on an MMAI #biomarker for estimating the risk of metastasis in patients with post-RP biochemical recurrence, May 5, 11:10 am - 11:20 am CT.

#ArteraOnTheGo

In a new video with UroToday.com, University of Toronto's Rashid Sayyid & Wellstar Health System's Zach Klaassen discuss the 2024 updates to the National Comprehensive Cancer Network (NCCN) #ProstateCancer Guidelines & how advanced tools like the #ArteraAI Prostate Test are 'transforming how we counsel our patients.' bit.ly/43KkimC

Join ArteraAI at #ESTRO !

We look forward to attending ESTRO's event to discuss the future of radiotherapy & power of #AI in the future of #cancertreatment decision-making.

Contact ArteraAI's @timshowalter1 to schedule your meeting at the event to learn more. #ArteraOnTheGo

As #NationalMinorityHealthMonth comes to a close, let's remember that awareness is not a one-month endeavor.

African American men have a 73% greater risk of #prostatecancer than White men. ZERO Prostate Cancer provides resources to keep the conversation going: bit.ly/3Unpqdf

ArteraAI's Dr. Laura Chang recently spoke about our MMAI #biomarker test at several Swedish institutions including Lund University Cancer Centre's mini-symposium for new #precisionmedicine tools for hormone-dependent cancers & Translational Cancer Research Day at Umeå University.

The ArteraAI team is headed to #AUA24 , May 3-6!

Don't miss Todd Morgan MD (Todd 〽️ Morgan, MD)'s presentation on an MMAI biomarker for estimating risk of metastasis in patients with post-RP biochemical recurrence, May 5, 11:10 am - 11:20 am CT.

#ArteraOnTheGo

Bruno was diagnosed with #prostatecancer in 2022. He shares how he was able to avoid ADT with the help of the #ArteraAI Prostate Test as he transitioned from #activesurveillance to radiation treatment - in the recent Active Surveillance Patients International panel: bit.ly/4aiqIM1

Get to know #ArteraAI 's Scott Houck, Scientific Communications Lead & April's Employee of the Month!

Scott is recognized for his consistent impact & efficiency on the team. Congratulations, Scott! 👏 We're proud to have you on our team.

#prostatecancer #AI #precisionmedicine

Join ArteraAI at #AUA24 !

We look forward to attending the Amer. Urol. Assn.'s annual meeting to discuss the latest, groundbreaking research, hear from #urology 's leading experts, and discuss the power of #AI in the future of #cancertreatment decisions.

#ArteraOnTheGo

Did you know: National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Prostate Cancer now include the #ArteraAI Prostate Test, making it the first AI-enabled prognostic and predictive test to be recommended for localized #prostatecancer !

➡️ Read more from Urology Times: bit.ly/3Udr9SB

According to GenesisCareUK & ProstateCancerResearch, 1 in 4 Black men will be diagnosed with #prostatecancer compared to 1 in 8 men of other ethnicities, yet under a quarter are aware of the higher risk: bit.ly/3J9Q4QD

Have the conversation.

#MinorityCancerWeek #MinorityHealthMonth

Ready to push the boundaries of AI in #cancertreatment ?

ArteraAI is seeking a #MachineLearning Engineer to develop AI-based #biomarkers to support the personalization of cancer therapy.

➡️ Apply today: bit.ly/43Q2FC0

ArteraAI's biomarker test uses a unique algorithm to analyze thousands of biopsy images & patient data. Handling large images is challenging. Partnering with Union_ai, we're tackling tasks beyond conventional methods to bring personalized cancer therapy: bit.ly/3U2nYNb

DYK: #ArteraAI models - developed using clinical trial data comprised of ~20% African Americans - can predict therapeutic benefit & estimate long-term outcomes to support personalized treatment decision-making.

➡️ Learn more: artera.ai

#MinorityHealthMonth #NMHM24

How is the ArteraAI #Prostate Test transforming how we counsel patients regarding treatment & outcomes?

University of Toronto's Rashid Sayyid & Wellstar Health System's Zach Klaassen discuss the 2024 updates to the National Comprehensive Cancer Network (NCCN) #Prostate Cancer Guidelines in a new video with UroToday.com: bit.ly/43KkimC

What are the four things every major #startup hub needs to be successful?

ArteraAI's own CEO & Co-Founder Andre Esteva, PhD shares the answer at @SXSW, as part of the panel 'Boomtown: Austin’s Next Startup Surge in Life Sciences': bit.ly/3IMpn42

#SXSW #SXSW 2024

ArteraAI benefits both clinicians & patients! 🤝

Our MMAI #biomarker test leverages the power of AI, predicting therapeutic benefit from hormone therapy and outperforming standard prognostic tools for patients with localized #prostatecancer : bit.ly/3FP86pB

Have you heard? 📣

The ArteraAI #ProstateTest has been included in National Comprehensive Cancer Network (NCCN)'s Clinical Practice Guidelines for Prostate Cancer, making it the first #AI -enabled tool of its kind to be recommended for localized #prostatecancer !

Read more from Targeted Oncology: bit.ly/3vqHGJd

What makes #LifeAtArtera so fulfilling?

🔹 We are passionate about what we do
🔹 We are making a difference
🔹 We are #remotefirst and work from anywhere

➡️ Apply today and join our mission to personalize therapy for cancer patients: bit.ly/447lNdk

The ArteraAI #ProstateTest predicts therapeutic benefit from hormone therapy and outperforms standard prognostic tools for patients with localized #prostatecancer .

Explore the science behind our #AI -enabled test: bit.ly/43aEzBK